Similar articles for PMID: 26407380

Year	Number of Results
1857	1
1858	1
1943	1
1960	1
1968	1
1970	1
1975	1
1978	1
1980	2
1981	1
1985	2
1986	2
1987	2
1988	1
1989	1
1992	1
1994	1
1995	1
1996	1
1997	1
1998	1
1999	2
2000	2
2001	2
2002	1
2003	3
2004	2
2005	2
2006	8
2007	4
2008	5
2009	10
2010	12
2011	7
2012	5
2013	9
2014	5
2015	11
2016	10
2017	13
2018	5
2019	14
2020	9
2021	5
2022	2

1

The direct cost of intravenous insulin infusions to the NHS in England and Wales.

Rajendran R, Scott A, Rayman G. Rajendran R, et al. Clin Med (Lond). 2015 Aug;15(4):330-3. doi: 10.7861/clinmedicine.15-4-330. Clin Med (Lond). 2015. PMID: 26407380 Free PMC article.

2

Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.

Holden SE, Morgan CL, Qiao Q, Jenkins-Jones S, Berni ER, Currie CJ. Holden SE, et al. Diabetes Obes Metab. 2017 Aug;19(8):1097-1105. doi: 10.1111/dom.12916. Epub 2017 Mar 31. Diabetes Obes Metab. 2017. PMID: 28218819

3

Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.

Giménez M, Elías I, Álvarez M, Quirós C, Conget I. Giménez M, et al. Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):377-383. doi: 10.1016/j.endinu.2017.04.006. Epub 2017 Jun 7. Endocrinol Diabetes Nutr. 2017. PMID: 28745609 English, Spanish.

4

[Human insulin vs. analogs. What is the cost of supplementary insulin therapy?].

Lundershausen R, Potthoff F, Häuser C, Kaiser M, Münscher C. Lundershausen R, et al. MMW Fortschr Med. 2006 Nov 9;148(45):42. MMW Fortschr Med. 2006. PMID: 17615748 German. No abstract available.

5

The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.

McGuire A, Irwin DE, Fenn P, Gray A, Anderson P, Lovering A, MacGowan A. McGuire A, et al. Value Health. 2001 Sep-Oct;4(5):370-5. doi: 10.1046/j.1524-4733.2001.45049.x. Value Health. 2001. PMID: 11705127 Free article.

6

Resource utilization with insulin pump therapy for type 2 diabetes mellitus.

Lynch PM, Riedel AA, Samant N, Fan Y, Peoples T, Levinson J, Lee SW. Lynch PM, et al. Am J Manag Care. 2010;16(12):892-6. Am J Manag Care. 2010. PMID: 21348559 Free article.

7

Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.

Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM. Valentine WJ, et al. Diabetes Res Clin Pract. 2015 Jul;109(1):95-103. doi: 10.1016/j.diabres.2015.04.023. Epub 2015 Apr 21. Diabetes Res Clin Pract. 2015. PMID: 25989713

8

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP. Plosker GL, et al. Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.

9

Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.

Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer BF, Reznik Y, de Valk HW. Roze S, et al. J Med Econ. 2016 Aug;19(8):742-9. doi: 10.3111/13696998.2016.1167695. Epub 2016 Apr 5. J Med Econ. 2016. PMID: 26985982 Free article.

10

Comparing insulin vials to pens--comparison of charges, not healthcare benefits.

Thethi TK. Thethi TK. J Med Econ. 2013 Oct;16(10):1228-30. doi: 10.3111/13696998.2013.832259. Epub 2013 Sep 5. J Med Econ. 2013. PMID: 23926888 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed